Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784351 | 0.91 | SIGMAR1 (0.57) | SIGMAR1SLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL9398493 | 0.86 | SIGMAR1 (0.61) | SIGMAR1SLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL3143023 | 0.84 | CYP2D6 (0.68) | SIGMAR1CYP2D6 | |
| SCHEMBL20689718 | 0.79 | ADRA1D (0.65) | SIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL11518881 | 0.79 | CYP2D6 (0.60) | SIGMAR1CYP2D6 | |
| SCHEMBL5774801 | 0.77 | FAAH (0.57) | KCNH2CYP2D6ADRA1DADRA1AADRA1B | |
| SCHEMBL11699939 | 0.77 | SIGMAR1 (0.60) | SIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL16695191 | 0.77 | CYP2D6 (0.50) | SIGMAR1SLC6A4SLC6A3CYP2D6HTR1A | |
| SCHEMBL2600465 | 0.77 | DPP7 (0.52) | SIGMAR1SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL2291008 | 0.76 | SIGMAR1 (1.00) | SIGMAR1SLC6A4KCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| CN-101341126-A | Antibacterial active 5-chinolin derivative | MORPHOCHEM AG FUER KOM (DE) | 2009-01-07 | — | — | CN | disclosed |
| EP-1943222-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | SIGMAR1 3099/4885SLC6A4 3191/4885KCNH2 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.